

Maria do Carmo Costa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1660874/publications.pdf>

Version: 2024-02-01

35
papers

1,599
citations

331259

21
h-index

360668

35
g-index

42
all docs

42
docs citations

42
times ranked

1496
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered retinal structure and function in Spinocerebellar ataxia type 3. <i>Neurobiology of Disease</i> , 2022, 170, 105774.	2.1	4
2	Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. <i>Neurobiology of Disease</i> , 2020, 137, 104697.	2.1	12
3	Recent therapeutic prospects for Machado-Joseph disease. <i>Current Opinion in Neurology</i> , 2020, 33, 519-526.	1.8	11
4	The Deubiquitinating Enzyme Ataxin-3 Regulates Ciliogenesis and Phagocytosis in the Retina. <i>Cell Reports</i> , 2020, 33, 108360.	2.9	23
5	In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3. <i>Movement Disorders</i> , 2020, 35, 1774-1786.	2.2	23
6	Ataxin-3 Links NOD2 and TLR2 Mediated Innate Immune Sensing and Metabolism in Myeloid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1495.	2.2	11
7	Antisense oligonucleotide therapy rescues aggregates formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line. <i>Stem Cell Research</i> , 2019, 39, 101504.	0.3	35
8	Selection of Reference Genes for Normalization of Gene Expression Data in Blood of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) Subjects. <i>Journal of Molecular Neuroscience</i> , 2019, 69, 450-455.	1.1	5
9	Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. <i>Molecular Neurobiology</i> , 2019, 56, 3690-3701.	1.9	24
10	Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. <i>Human Molecular Genetics</i> , 2017, 26, 1419-1431.	1.4	40
11	Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. <i>Brain</i> , 2016, 139, 2891-2908.	3.7	37
12	Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3. <i>Neurobiology of Disease</i> , 2015, 82, 281-288.	2.1	24
13	A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. <i>Human Molecular Genetics</i> , 2015, 24, 1211-1224.	1.4	41
14	Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells. <i>Human Molecular Genetics</i> , 2015, 24, 100-117.	1.4	26
15	Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice. <i>Molecular Therapy</i> , 2013, 21, 1909-1918.	3.7	100
16	Toward RNAi Therapy for the Polyglutamine Disease Machado-Joseph Disease. <i>Molecular Therapy</i> , 2013, 21, 1898-1908.	3.7	102
17	New hope for therapy in neurodegenerative diseases. <i>Cell Research</i> , 2013, 23, 1159-1160.	5.7	4
18	Toward understanding Machado-Joseph disease. <i>Progress in Neurobiology</i> , 2012, 97, 239-257.	2.8	228

#	ARTICLE	IF	CITATIONS
19	Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3. <i>Journal of Neuroscience</i> , 2011, 31, 13002-13014.	1.7	190
20	Increased transcript diversity: novel splicing variants of Machado-Joseph Disease gene (ATXN3). <i>Neurogenetics</i> , 2010, 11, 193-202.	0.7	37
21	Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. <i>Neurobiology of Disease</i> , 2010, 40, 163-176.	2.1	62
22	Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 1154-1163.	1.9	42
23	Ataxin-3 Plays a Role in Mouse Myogenic Differentiation through Regulation of Integrin Subunit Levels. <i>PLoS ONE</i> , 2010, 5, e11728.	1.1	25
24	Functional genomics and biochemical characterization of the <i>C. elegans</i> orthologue of the Machado-Joseph disease protein ataxin-3. <i>FASEB Journal</i> , 2007, 21, 1126-1136.	0.2	62
25	The CAG repeat at the Huntington disease gene in the Portuguese population: insights into its dynamics and to the origin of the mutation. <i>Journal of Human Genetics</i> , 2006, 51, 189-195.	1.1	29
26	Exclusion of mutations in the PRNP, JPH3, TBP, ATN1, CREBBP, POU3F2 and FTL genes as a cause of disease in Portuguese patients with a Huntington-like phenotype. <i>Journal of Human Genetics</i> , 2006, 51, 645-651.	1.1	26
27	Nonsense mutation in TITF1 in a Portuguese family with benign hereditary chorea. <i>Neurogenetics</i> , 2005, 6, 209-215.	0.7	59
28	Population Genetics of Wild-Type CAG Repeats in the Machado-Joseph Disease Gene in Portugal. <i>Human Heredity</i> , 2005, 60, 156-163.	0.4	43
29	Towards a Structural Understanding of the Fibrillization Pathway in Machado-Joseph's Disease: Trapping Early Oligomers of Non-expanded Ataxin-3. <i>Journal of Molecular Biology</i> , 2005, 353, 642-654.	2.0	68
30	Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. <i>Multiple Sclerosis Journal</i> , 2004, 10, 153-157.	1.4	27
31	Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. <i>Genomics</i> , 2004, 84, 361-373.	1.3	26
32	Molecular diagnosis of Huntington disease in Portugal: implications for genetic counselling and clinical practice. <i>European Journal of Human Genetics</i> , 2003, 11, 872-878.	1.4	18
33	Identification of three novel polymorphisms in the MJD1 gene and study of their frequency in the Portuguese population. <i>Journal of Human Genetics</i> , 2002, 47, 205-207.	1.1	5
34	Improvement in the Molecular Diagnosis of Machado-Joseph Disease. <i>Archives of Neurology</i> , 2001, 58, 1821.	4.9	121
35	The Deubiquitinating Enzyme Ataxin-3 Regulates Ciliogenesis and Phagocytosis in the Retina. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0